Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 01:16am CEST

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; [email protected]

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
06/23 TESARO INC (NASDAQ : TSRO) Might Outperform Rivals with Zejula
06/23 ASTRAZENECA : Faslodex CHMP positive opinion in 1L breast cancer
06/23 ASTRAZENECA : Faslodex (fulvestrant) receives positive CHMP opinion for use in 1..
06/22 REPORTS FROM ASTRAZENECA ADD NEW DAT : ...
06/22 INVESTIGATORS AT ASTRAZENECA ZERO IN : DLBCL, NHL and...
06/22 ASTRAZENECA : Studies from AstraZeneca Update Current Data on Inflammation (Iden..
06/22 TROVAGENE : Enters Into Agreement with AstraZeneca to Utilize Trovera® ctDNA Tes..
06/22 China Medical City incubator attracts UK interest
06/22 ASTRAZENECA : Clinical trial deems AstraZenecas Lynparza better for mutation-cau..
06/22 United States Anesthesia Drugs Market & Forecast
More news
Sector news : Pharmaceuticals - NEC
09:28a CROWN RESORTS : China jails Crown Resorts staff over gambling crimes
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/23 European Ad Com backs expanded use of AstraZeneca's breast cancer med Faslode..
06/22 AstraZeneca (AZNCF)Presents At JP Morgan European Healthcare Conference - Sli..
06/22 Drug stocks rally on GOP draft of healthcare bill
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/21 AstraZeneca (AZN) Presents At 2017 Wells Fargo West Coast Energy Conference -..
Advertisement
Financials ($)
Sales 2017 21 493 M
EBIT 2017 5 890 M
Net income 2017 2 622 M
Debt 2017 12 464 M
Yield 2017 3,97%
P/E ratio 2017 32,00
P/E ratio 2018 25,47
EV / Sales 2017 4,62x
EV / Sales 2018 4,50x
Capitalization 86 930 M
More Financials
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 67,6 $
Spread / Average Target -1,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA21.71%86 691
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results